Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients

Hypertension

Volumn 66, Issue 2, 2015, Pages 368-373

  Okin, Peter M ^a   Hille, Darcy A ^b   Larstorp, Anne Cecilie K ^c   Wachtell, Kristian ^a   Kjeldsen, Sverre E ^c   Dahlöf, Björn ^d,e   Devereux, Richard B ^a,f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF OSLO   (Norway)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e Örebro University   (Sweden)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atrial fibrillation; Blood pressure; Electrocardiography; Hypertension; Hypertrophy

Indexed keywords

ATENOLOL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID; ANTIHYPERTENSIVE AGENT;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPERTROPHY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NEW-ONSET ATRIAL FIBRILLATION; PREDICTIVE VALUE; PRIORITY JOURNAL; QRS INTERVAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE; ATRIAL FIBRILLATION; BLOOD PRESSURE; COMPLICATION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; ELECTROCARDIOGRAPHY; INCIDENCE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; REGRESSION ANALYSIS; RISK FACTOR; SYSTOLE; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; ATRIAL FIBRILLATION; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; LOSARTAN; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; SYSTOLE; TREATMENT OUTCOME;

EID: 84937552706     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05728     Document Type: Article

References (40)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE., Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
2. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ., Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004;110:1042-1046. doi: 10.1161/01.CIR.0000140263.20897.42
3. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB., Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-719. doi: 10.1016/j.jacc.2004.10.068
4. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D., Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998;98:946-952.
5. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE., The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-484. doi: 10.1016/S0002-9343(99)80348-9
6. Okin PM, Bang CN, Wachtell K, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB., Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Circ Arrhythm Electrophysiol 2013;6:243-251. doi: 10.1161/CIRCEP.112.977777
7. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, Carolei A., Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: Results from a population-based study. Stroke 2005;36:1115-1119. doi: 10.1161/01.STR.0000166053.83476.4a
8. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, Carluccio E, Sardone MG, Porcellati C., Atrial fibrillation in hypertension: Predictors and outcome. Hypertension 2003;41:218-223.
9. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA., Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-844.
10. Vaziri SM, Larson MG, Benjamin EJ, Levy D., Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 1994;89:724-730.
11. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM., Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997;96:2455-2461.
12. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A., Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123:1501-1508. doi: 10.1161/CIRCULATIONAHA.110.009035
13. Mitchell GF, Vasan RS, Keyes MJ, Parise H, Wang TJ, Larson MG, D'Agostino RB Sr, Kannel WB, Levy D, Benjamin EJ., Pulse pressure and risk of new-onset atrial fibrillation. JAMA 2007;297:709-715. doi: 10.1001/jama.297.7.709
14. Thomas MC, Dublin S, Kaplan RC, Glazer NL, Lumley T, Longstreth WT Jr, Smith NL, Psaty BM, Siscovick DS, Heckbert SR., Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens 2008;21:1111-1116. doi: 10.1038/ajh.2008.248
15. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE., Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000;160:1612-1617.
16. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G, Cardio-Sis Investigators Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): An open-label randomised trial. Lancet 2009;374:525-533. doi: 10.1016/S0140-6736(09)61340-4
17. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM., Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009;119:2146-2152. doi: 10.1161/CIRCULATIONAHA.108.830042
18. Larstorp AC, Ariansen I, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM, Dahlöf B, Kjeldsen SE, Wachtell K., Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Hypertension 2012;60:347-353. doi: 10.1161/HYPERTENSIONAHA.112.195032
19. Grundvold I, Skretteberg PT, Liestøl K, Erikssen G, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J., Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: A 35-year follow-up study. Hypertension 2012;59:198-204. doi: 10.1161/HYPERTENSIONAHA.111.179713
20. The ACCORD Study Group Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585.
21. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ., Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-68. doi: 10.1001/jama.2010.884
22. JATOS Study Group Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008;31:2115-2127.
23. Okin PM, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB., Impact of lower achieved blood pressure on outcomes in hypertensive patients. J Hypertens 2012;30:802-810.; discussion 810. doi: 10.1097/HJH.0b013e3283516499
24. Lv J, Neal B, Ehteshami P, Ninomiya T, Woodward M, Rodgers A, Wang H, MacMahon S, Turnbull F, Hillis G, Chalmers J, Perkovic V., Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: A systematic review and meta-analysis. PLoS Med 2012 9 e1001293. doi: 10.1371/journal.pmed.1001293
25. Mancia G, Grassi G., Aggressive blood pressure lowering is dangerous: The J-curve: Pro side of the arguement. Hypertension 2014;63:29-36. doi: 10.1161/01.hyp.0000441190.09494.e9
26. Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Reboldi G., Aggressive blood pressure lowering is dangerous: The J-curve: Con side of the arguement. Hypertension 2014;63:37-40. doi: 10.1161/01.hyp.0000439102.43479.43
27. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B., Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006;296:1242-1248. doi: 10.1001/jama.296.10.1242
28. Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB., Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: The LIFE study. Circ Arrhythm Electrophysiol 2008;1:337-343. doi: 10.1161/CIRCEP.108.795351
29. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H., The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: Rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997;10(7 Pt 1) 705-713.
30. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003. doi: 10.1016/S0140-6736(02)08089-3
31. Okin PM, Roman MJ, Devereux RB, Kligfield P., Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995;25:417-423.
32. Sokolow M, Lyon TP., The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949;37:161-186.
33. Snappin SM, Jiamg Q, Iglewicz B., Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimate. Am Stat 2005;59:310-307.
34. Verdecchia P, Mazzotta G, Angeli F, Reboldi G., Above which blood pressure level does the risk of atrial fibrillation increase? Hypertension 2012;59:184-185. doi: 10.1161/HYPERTENSIONAHA.111.187260
35. Ambrosius WT, Sink KM, Foy CG, SPRINT Study Research Group The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 2014;11:532-546. doi: 10.1177/1740774514537404
36. Wachtell K, Bella JN, Rokkedal J, Palmieri V, Papademetriou V, Dahlöf B, Aalto T, Gerdts E, Devereux RB., Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002;105:1071-1076.
37. Okin PM, Gerdts E, Wachtell K, Oikarinen L, Nieminen MS, Dahlöf B, Devereux RB., Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: Implications for the development of new atrial fibrillation. J Hypertens 2010;28:1534-1540.
38. Deroubaix E, Folliguet T, Rücker-Martin C, Dinanian S, Boixel C, Validire P, Daniel P, Capderou A, Hatem SN., Moderate and chronic hemodynamic overload of sheep atria induces reversible cellular electrophysiologic abnormalities and atrial vulnerability. J Am Coll Cardiol 2004;44:1918-1926. doi: 10.1016/j.jacc.2004.07.055
39. Oakes RS, Badger TJ, Kholmovski EG, Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 2009;119:1758-1767. doi: 10.1161/CIRCULATIONAHA.108.811877
40. Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Nieminen MS, Olsen MH, Okin PM, Palmieri V, Rokkedal JE, Devereux RB., In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Press 2010;19:169-175. doi: 10.3109/08037051.2010.481811